|
시장보고서
상품코드
2084832
소아 결신 발작 간질 치료 시장 : 약제별, 질환 유형별, 지역별Childhood Absence Epilepsy Treatment Market, By Drug, By Disease Type, By Geography |
||||||
소아 결신 발작 간질 치료 시장은 2026년에 3억 달러 규모에 달할 것으로 추정되고 있으며, 2033년까지 5억 2,000만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 8.2%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 3억 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 8.20% | 2033년 시장 규모 예측 : | 5억 2,000만 달러 |
소아 결신성 간질의 진단은 증상을 파악하고, 그 증상에 기반하여 간질의 유형를 분류하는 데 중점을 둡니다. 소아 결신성 간질의 진단 방법 및 기술에는 뇌파 검사(EEG)/비디오 텔레메트리, 자기공명영상(MRI 스캔), 그리고 혈액 검사가 포함됩니다. 뇌파 검사(EEG)/비디오 텔레메트리에서는 환자에게 3-5분간 과호흡을 하게 하여 결신 발작을 유발함으로써, 뇌에서 발생하는 전기 신호를 컴퓨터에 기록합니다. 그 결과, 뇌파(EEG)에서 3 Hz(1초당 주파수)의 스파이크-웨이브 방전이 관찰되었으며, 그 특성이 전신성(뇌 양쪽에서 유사한 패턴)임이 확인되었습니다. 간질의 근본적인 원인은 MRI 검사를 통해 파악할 수 있습니다(뇌 손상으로 인한 간질을 앓고 있는 환자 중에는 MRI 검사를 통해 발견되는 경우도 있기 때문입니다). 또한 간질의 원인이 될 가능성이 있는 기저 질환을 진단하기 위해 혈액 검사가 필요한 경우가 있습니다.
시장 역학
시장의 주요 기업은 소아 결손성 간질 치료를 위한 신약 개발에 주력하고 있습니다. 이 질환의 유병률 증가, 의약품 접근성 향상, 그리고 소아 결손성 간질 치료를 위해 개발중인 의약품(Insys Therapeutics 및 Cavion, Inc.)의 존재와 같은 요인들이 전 세계 소아 결손성 간질 치료 시장의 성장을 촉진할 것으로 예상됩니다. 또한 미국 및 세계 각국의 제네릭 의약품 제조사들이 신제품을 출시하는 것도 시장 성장을 지원할 것으로 전망됩니다. 예를 들어 Dr. Reddy’s Laboratories사는 2016년에 미국에서 라모트리진 제네릭 구강내 용해정을 출시했습니다. 또한 Insys Therapeutics사(칸나비디올)와 Cavion, Inc.사(CX-8998) 등 많은 제약사가 2상 임상시험 단계에 있는 약물을 보유하고 있으며, 이러한 치료제는 예측 기간 내에 출시될 전망입니다.
본 조사의 주요 특징
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한 본 조사에서는 시장 촉진요인, 시장 억제요인, 기회, 신제품 출시 및 승인, 지역별 전망, 그리고 주요 기업이 채택하고 있는 경쟁 전략에 관한 중요 인사이트도 제공하고 있습니다.
- 본 조사에서는 다음의 파라미터(기업 개요, 재무 실적, 제품 포트폴리오, 사업 전개 지역, 유통 전략, 주요 발전 및 전략)를 바탕으로, 전 세계 소아 결손성 간질 치료 시장의 주요 기업 개요을 소개하고 있습니다.
- 이 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 기술 업그레이드, 시장 확대 및 마케팅 전략에 대해 충분한 정보를 바탕으로 의사결정을 내릴 수 있게 됩니다.
- 이 '세계의 소아 결손성 간질 치료 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 소아 결손성 간질 치료 시장 분석에 활용되는 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 소아 결신 발작 간질 치료 시장 : 약물별, 2021-2033년
제5장 세계의 소아 결신 발작 간질 치료 시장 : 질환 유형별, 2021-2033년
제6장 세계의 소아 결신 발작 간질 치료 시장 : 지역별, 2021-2033년
제7장 경쟁 구도
제8장 섹션
KSA 26.07.14Childhood Absence Epilepsy Treatment Market is estimated to be valued at USD 300 Mn in 2026 and is expected to reach USD 520 Mn by 2033, growing at a compound annual growth rate (CAGR) of 8.2% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 300 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.20% | 2033 Value Projection: | USD 520 Mn |
Childhood absence epilepsy diagnosis revolves around identifying symptoms and categorizing the epilepsy type based on those symptoms. Diagnostic methods and techniques for childhood absence epilepsy include electroencephalogram (EEG)/video telemetry, magnetic resonance imaging (MRI scans), and blood tests. In electroencephalogram (EEG)/video telemetry, electrical signals from brain are recorded in a computer by asking the patient to hyperventilate for 3 to 5 minutes, which triggers an absence seizure. The EEG then shows spikes and wave discharges at 3 Hz (cycles per second) that are generalized in nature (similar on both sides of the brain). Structural causes behind epilepsy can be understood with the help of MRI scans (as some patients suffering from epilepsy due to brain damage can be found by a MRI scan). Blood tests may be required to diagnose any medical conditions, which may be the reason behind epilepsy.
Market Dynamics
Key players in the market are focused on the development of new drugs for the treatment of childhood absence epilepsy. Factors such as increasing prevalence of the disease, increasing accessibility of medications, and presence of drugs in pipeline for childhood absence epilepsy treatment (Insys therapeutics and Cavion, Inc.) are expected to boost the global childhood absence epilepsy treatment market growth. Product launches by generic manufacturers in the U.S. as well as globally is expected to support growth of the market. For instance, Dr. Reddy's Laboratories launched generic lamotrigine orally disintegrating tablets in the U.S. in 2016. Moreover, a number of manufacturers such as Insys Therapeutics (Cannabidiol) and Cavion, Inc. (CX-8998) have drugs in phase II stage in clinical trials and these therapies are expected to be launched over the forecast period.
Key features of the study
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global childhood absence epilepsy treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies
- Key companies covered as a part of this study include Cavion, Inc., Pfizer, Inc., GlaxoSmithKline Plc, Insys Therapeutics, Inc., AbbVie, Inc., and Teva Pharmaceutical Industries Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, by technology up-gradation, market expansion, and marketing tactics
- The global childhood absence epilepsy treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision making through various strategy matrices used in analyzing the childhood absence epilepsy treatment market
Market Segmentation
- By Drug (Revenue, USD Mn, 2021-2033)
- Ethosuximide
- Valproate
- Lamotrigine
- Phase 2 Drugs
- Cannabidiol Oral Solution
- CX-8998
- By Disease Type (Revenue, USD Mn, 2021-2033)
- Typical Absence Seizures
- Atypical Absence Seizures
- By Region (Revenue, USD Mn, 2021-2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Key Players
- Cavion, Inc.
- Pfizer, Inc.
- GlaxoSmithKline Plc
- Insys Therapeutics, Inc.
- AbbVie, Inc.
- Teva Pharmaceutical Industries Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug
- Market Snapshot, By Disease Type
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Product Approval
- Collaboration/Merge/Acquisition
- Regulatory Landscape
- PEST Analysis
- Porter's Five Forces Analysis
- Epidemiology
- Robust Pipeline Analysis
4. Global Childhood Absence Epilepsy Treatment Market, By Drug, 2021 - 2033, (USD Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Ethosuximide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Valproate
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Lamotrigine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Phase 2 Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Segment Trends
- Cannabidiol Oral Solution
- CX-8998
5. Global Childhood Absence Epilepsy Treatment Market, By Disease Type, 2021 - 2033, (USD Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Typical Absence Seizures
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Atypical Absence Seizures
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
6. Global Childhood Absence Epilepsy Treatment Market, By Region, 2021 - 2033, (USD Million)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Million)
- North Africa
- Central Africa
- South Africa
7. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Company Profile
- Cavion, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Pfizer, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- GlaxoSmithKline Plc
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Insys Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- AbbVie, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Cavion, Inc.
- Analyst Views
8. Section
- References
- Research Methodology
- About Us
